Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07437950 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 5 years 3 months later May 31, 2029 → Sep 22, 2034
See other at-risk trials from National Cancer Institute (NCI)

Record History

  1. Trial sites expanded: 34 → 37 locations
  2. Study sites: 34 to 37
  3. Start date changed from estimate of Apr 18, 2027 to Sep 25, 2026 Study sites: 33 to 34 Show 1 more changeShow less
    • Study sites: 33 to 34
  4. Study sites: 32 to 33 Start date changed from estimate of Apr 18, 2027 to Sep 25, 2026 Show 1 more changeShow less
    • Start date changed from estimate of Apr 18, 2027 to Sep 25, 2026
  5. Trial sites expanded: 28 → 31 locations
Show 5 earlier versionsHide 5 earlier versions
  1. Study sites: 28 to 31 Eligibility criteria expanded, about 32 words · Secondary endpoints: details revised at 4 of 8 entries Show 2 more changesShow less
    • Eligibility criteria expanded, about 32 words
    • Secondary endpoints: details revised at 4 of 8 entries
  2. Site details revised at 1 of 28 sitesv41
  3. Study sites: 27 to 28v40
  4. Study sites: 26 to 27v39
  5. Study sites: 25 to 26v38
  1. Trial sites expanded: 7 → 23 locationsv37
  2. Study sites: 7 to 23v36
  3. Recruitment opened Start date: Oct 14, 2026 to Apr 18, 2027 · Trial sites expanded: 0 → 7 locations · Eligibility criteria expanded, about 9 words · 2 morev35 Show 5 more changesShow less
    • Start date: Oct 14, 2026 to Apr 18, 2027
    • Trial sites expanded: 0 → 7 locations
    • Eligibility criteria expanded, about 9 words
    • Secondary endpoints: 7 to 8
    • Study description revised

    See this version in full on ClinicalTrials.gov ↗

  4. Primary and study completion pushed from May 31, 2029 to Sep 22, 2034v34
  5. 32 versions Re-verified since Feb 27, 2026, no change to tracked fieldsv2-v33
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase II MyeloMATCH treatment trial compares ASTX727 with standard duration versus shorter duration of venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML). ASTX727 is a combination of decitabine and cedazuridine. Decitabine is in a class of medications called hypomethylation agents. It works by helping the bone marrow produce normal blood cells and by killing abnormal cells in the bone marrow. Cedazuridine is in a class of medications called cytidine deaminase inhibitors. It prevents the breakdown of decitabine, making it more available in the body so that decitabine will have a greater effect. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Shorter duration venetoclax may be as effective as standard duration venetoclax when given with ASTX727 for the treatment of newly diagnosed AML.
Trial Details
NCT Number NCT07437950
Lead Sponsor National Cancer Institute (NCI)
Conditions Acute Myeloid Leukemia
Enrollment 126 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov